| Miscellaneous Clinical Trials |
A RANDOMIZED, UNBLÎNDED, SINGLE RESEARCH SITE, COMPARATOR STUDY OF RAISINS VERSUS ALTERNATIVE SNACKS ON CARDIOVASCULAR RISK FACTORS IN GENERALLY HEALTHY SUBJECTS A 6-MONTH, PHASE 3, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE INCIDENCE OF GASTRIC ULCERS FOLLOWING ADMINISTRATION OF EITHER PA32540 OR ENTERIC COATED ASPIRIN 325 MG IN SUBJECTS WHO ARE AT RISK FOR DEVELOPING ASPIRIN-ASSOCIATED ULCERS A WORLDWIDE, OPEN LABEL, CLINICAL TRIAL TO EXAMINE THE LONG TERM SAFETY AND TOLERABILITY OF RIZATRIPTAN IN PEDIATRIC MIGRAINEURS 12 TO 17 YEARS OF AGE FOR THE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA. A WORLDWIDE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP CLINICAL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF RIZATRIPAN FOR THE ACUTE TREATMENT OF MIGRAINE IN CHILDREN AND ADOLESCENTS. A PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, IMMUNOGENICITY, SAFETY, AND TOLERABILITY OF ZOSTAVAX IN SUBJECTS 50-59 YEARS OF AGE A CLINICAL OUTCOMES STUDY OF DARAPLADIB VERSUS PLACEBO IN SUBJECTS WITH CHRONIC CORONARY HEART DISEASE TO COMPARE THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE). THE STABILIZATION OF ATHEROSCLEROTIC PLAQUE BY INITIATION OF DARAPLADIB THERAPY TRIAL (STABILITY) A PHASE IIA, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-0974 FOR MIGRAINE PROPHYLAXIS IN PATIENTS WITH EPISODIC MIGRAINE. A MULTI-CENTER, LONG-TERM, OPEN-LABEL EXTENSION STUDY OF [S,S]-REBOETINE (PNU-165442G) ADMINISTERED ONCE DAILY IN PATIENTS WITH FIBROMYALGIAS A PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, IMMUNOGENICITY, SAFETY AND TOLERABILITY OF ZOSTAVAX IN SUBJECTS 50 - 59 YEARS OF AGE A 14-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY OF [S,S]-REBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY (QD) IN PATIENTS WITH FIBROMYALGIA A MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP MULTIPLE ATTACKS STUDY TO COMPARE THE EFFICACY AND SAFETY OF ORAL MK-0974 WITH PLACEBO FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA A MULTICENTER, DOUBLE-BLIND, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO COMPARE THE EFFICACY AND SAFETY OF ORAL MK-0974 WITH PLACEBO AND ZOLMITRIPTAN FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA A MULTICENTER, DOUBLE-BLIND, ACTIVE-CONTROLLED, PARALLEL GROUP STUDY TO EXAMINE THE SAFETY, TOLERABILITY AND EFFICACY OF ORAL MK-0974 FOR THE LONG TERM TREATMENT OF ACUTE MIGRAINE WITH OR WITHOUT AURA A RANDOMIZED-WITHDRAWAL PHASE III STUDY EVALUATING THE SAFETY AND EFFICACY OF CG5503 EXTENDED-RELEASE (ER) IN SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY (DPN) A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3, THREE ARM STUDY OF THE SAFETY AND EFFICACY OF PIRFENIDONE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 STUDY TO EVAUATE THE LONG-TERM SAFETY OF ALVIMOPAN 0.5 MG TWICE DAILY FOR 12 MONTHS FOR THE TREATMENT OF OPIOID-INDUCED BOWEL DYSFUNCTION IN ADULTS TAKING OPIOID THERAPY FOR PERSISTENT NON-CANCER PAIN. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY ALVIMOPAN 0.5MG ONCE DAILY AND 0.5MG TWICE DAILY FOR 12 WEEKS FOR THE TREATMENT OF OPIOID-INDUCED BOWEL DYSFUNCTION IN ADULTS TAKING OPIOID THERAPY FOR PERSISTENT NON-CANCER PAIN RANDOMIZED, DOUBLE-BLIND, PLACEBO AND ACTIVE-CONTROLLED, PARALLEL, MULTICENTER STUDY TO ASSESS THE SAFETY AND EFFICACY OF 3 ½ DAY COMBINATIONS OF 17B-ESTRADIOL/NORETHINDRONE ACETATE TRANSDERMAL DELIVERY SYSTEMS FOR RELIEF OF MENOPAUSAL VASOMOTOR SYMPTOMS AND REDUCTION OF ENDOMETRIAL HYPERPLASIA A DOUBLE-BLIND, PARALLEL, PLACEBO CONTROLLED, MULTICENTER, POLYSOMOGRAPHIC STUDY OF THE EFFECTS OF L-759274 AND ZOLPIDEM IN PATIENTS WITH CHRONIC INSOMNIA |